Recent Updates
Recently added Catalysts
NGNE Positive Sentiment

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Neurogene Inc. announced an Inducement Grant under Nasdaq Rule 5635(c)(4). The Compensation Committee approved stock options for 2,010 shares to a new employee, effective November 3, 2026. This initiative aims to enhance the company's talent pool as it develops genetic medicines for rare neurological diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Neurogene approved stock options for a new employee.
  • The grant aims to attract talent to the company.
  • The company focuses on genetic medicines for rare diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
7.5%
average across 2 past catalysts
Cash runway
~26 mo
Minimal dilution risk
Lead asset
NL-201
Phase 1 · Solid Tumor

Full Press Release Details

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,010 shares of the Company’s common stock to one new employee (the “Inducement Grant”) on November 3, 2026 (the “Grant Date”). The Induceme

Frequently Asked Questions

What is the Inducement Grant by Neurogene?

It is a grant of stock options to a new employee approved by the Compensation Committee.

How many shares are included in the Inducement Grant?

The grant includes an aggregate of 2,010 shares of common stock.

When is the effective date of the stock options?

The stock options are effective on November 3, 2026.

What is Neurogene's focus?

Neurogene focuses on developing genetic medicines for rare neurological diseases.

ShareAdd on Google
Tags: NGNE Neurogene stock options genetic medicines rare diseases
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$225M liquidity · $8M/mo burn
~26 mo
Minimal dilution risk
Lead asset
NL-201Phase 1
Solid Tumor →

Catalyst track record

+41%
best trade around NGNE's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for NGNE.

See every catalyst's timing & PoA →